Evidence map›Paper›PMID 28474578›Full record

ArticleBioMedicine2017

Kuei-Lu-Er-Xian-Jiao extract enhances BMP-2 production in osteoblasts.

Min-Huan Wu, Ting-Hsuan Lee, Hsiang-Ping Lee, Te-Mao Li, I-Tee Lee, Po-Chuen Shieh, Chih-Hsin Tang

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Observational
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Min-Huan WuPhysical Education Office, Tunghai University, Taichung 407, Taiwan - Sports Recreation and Health Management Continuing Studies, Tunghai University, Taichung 407, Taiwan.
Ting-Hsuan LeeSchool of Pharmacy, Tajen University, Pingtung 907, Taiwan.
Hsiang-Ping LeeGraduate Institute of Chinese Medicine, China Medical University, Taichung 404, Taiwan - Department of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan.
Te-Mao LiGraduate Institute of Chinese Medicine, China Medical University, Taichung 404, Taiwan.
I-Tee LeeDepartment of Chinese Medicine, China Medical University Hospital, Taichung 404, Taiwan - Division of Endocrinology and Metabolism, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan - Graduate Institute of Basic Medical Science, China Medical University, Taichung 404, Taiwan.
Po-Chuen ShiehSchool of Pharmacy, Tajen University, Pingtung 907, Taiwan.
Chih-Hsin TangGraduate Institute of Basic Medical Science, China Medical University, Taichung 404, Taiwan - Department of Pharmacology, School of Medicine, China Medical University, Taichung 404, Taiwan - Department of Biotechnology, College of Health Science, Asia University, Taichung 413, Taiwan.
Tajen University · TWChina Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteoporosis is a common skeletal disorder, resulting from an imbalance in bone resorption relative to formation. Bone morphogenetic protein (BMP) is a key regulator in bone formation and osteoblastic differentiation. Hence, compounds that promote BMP expression may be suitable candidates for osteoporosis treatment. This study examined the effects of the traditional Chinese medicinal agent, Kuei-Lu-Er-Xian-Jiao (KLEXJ), on BMP-2 production in osteoblasts. We found that KLEXJ extract promoted osteoblastic differentiation marker ALP activity and increased BMP-2 production; pretreatment with PI3K and Akt inhibitors, or small interfering RNA (siRNA), reduced these effects. KLEXJ also enhanced PI3K and Akt phosphorylation. Treatment of osteoblastic cells with NF-κB inhibitors (TPCK or PDTC) markedly inhibited KLEXJ-enhancement of ALP activity and BMP-2 production. KLEXJ also significantly promoted p65 phosphorylation, while treatment with PI3K and Akt inhibitors antagonized KLEXJ-enhanced p65 phosphorylation. Thus, KLEXJ enhances ALP activity and BMP-2 production of osteoblasts through the PI3K/Akt/ NF-κB signaling pathway and hence may be suitable in the treatment of osteoporosis.

Identifiers

PMID28474578
PMCPMC5439337
OpenAlexW2594224575

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.